Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia
Open Access
- 28 February 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (3) , sfae051
Abstract
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel therapeutic class for treating anemia in patients with chronic kidney disease. Small molecule analogs of α-ketoglutarate (AKG), an essential substrate for 2-oxoglutarate-dependent dioxygenases (2-OGDDs), including prolyl hydroxylase domain proteins (PHDs), inhibit PHDs pharmacologically and thereby prevent HIF degradation. HIF stabilization alleviates anemia through several stimulatory effects on erythropoiesis, but it also affects the expression of many anemia-unrelated genes whose protein products exert important functions in vivo. Therefore, the pleiotropic effects of HIF stabilization under normoxic conditions deserve to be examined in more detail. Specifically, we believe that particular attention should be given to epigenetic modifications among the various AKG-based metabolic systems that may be altered by HIF-PHIs. It is noteworthy that AKG has been reported to exert health-protective actions. AKG-based metabolic systems include enzymes associated with the tricarboxylic acid cycle and amino acid metabolism, as well as 2-OGDD-mediated processes, which play important roles in many biological reactions. In this review, we examine the multifaceted effects of HIF-PHIs, encompassing not only their on-target effect of HIF stabilization but also their off-target inhibitory effects on various AKG-based metabolic systems. Furthermore, we examine its potential relevance to cardiovascular complications, based on clinical and animal studies suggesting its involvement in vascular calcification, thrombogenesis and heart failure. In conclusion, although HIF-PHIs offer a promising avenue for anemia treatment in CKD patients, their broader impact on multiple biological systems raises substantial concerns. The intricate interplay between HIF stabilization, AKG competition and cardiovascular complications warrants extensive, long-term investigations to ensure the safety and usefulness of HIF-PHIs in clinical practice.Keywords
This publication has 94 references indexed in Scilit:
- Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophyCardiovascular Research, 2004
- Impaired platelet responses to thrombin and collagen in AKT-1–deficient miceBlood, 2004
- Oxygen sensing by HIF hydroxylasesNature Reviews Molecular Cell Biology, 2004
- Energy metabolism in heart failureThe Journal of Physiology, 2004
- Kidney Disease as a Risk Factor for Development of Cardiovascular DiseaseCirculation, 2003
- Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortalityNephrology Dialysis Transplantation, 2003
- Sequence Determinants in Hypoxia-inducible Factor-1α for Hydroxylation by the Prolyl Hydroxylases PHD1, PHD2, and PHD3Journal of Biological Chemistry, 2002
- Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor–1Blood, 2002
- Metabolism—the lost child of cardiology∗∗Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.JACC, 2000
- Arterial stiffening and vascular calcifications in end‐stage renal diseaseNephrology Dialysis Transplantation, 2000